Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.59 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | ACR | P10323 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18929891 | 0.80 | SLC9A1 (0.71) | SLC9A1SLC9A2CNR2 | |
| Cariporide SCHEMBL39639 | 0.77 | SLC9A1 (0.61) | SLC9A1SLC9A2PRSS1CNR2 | |
| SCHEMBL3972067 | 0.77 | SLC9A1 (0.60) | SLC9A1SLC9A2PRSS1CNR2 | |
| Cariporide SCHEMBL221094 | 0.76 | SLC9A1 (0.63) | SLC9A1SLC9A2PRSS1CNR2 | |
| Cariporide SCHEMBL6261845 | 0.76 | SLC9A1 (0.63) | SLC9A1SLC9A2PRSS1CNR2 | |
| Cariporide SCHEMBL1229789 | 0.76 | SLC9A1 (0.60) | SLC9A1SLC9A2PRSS1CNR2 | |
| Cariporide SCHEMBL220085 | 0.76 | SLC9A1 (0.60) | SLC9A1SLC9A2PRSS1CNR2 | |
| SCHEMBL3968070 | 0.75 | SLC9A1 (0.64) | SLC9A1SLC9A2CNR2 | |
| Guanidine SCHEMBL6354167 | 0.74 | SLC9A1 (0.63) | SLC9A1 | |
| SCHEMBL3976379 | 0.74 | SLC9A1 (0.62) | SLC9A1SLC9A2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1532978-A1 | REMEDY FOR URINARY FREQUENCY AND URINARY INCONTINENCE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | SLC14A1, SLC26A4, SLC6A12 | SLC9A1 39/4885SLC9A2 50/4885PRSS1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.